Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced…

By B. Chauffert, F. Mornex, F. Bonnetain, P. Rougier, C. Mariette, O. Bouché, J. Bosset, T. Aparicio, L. Mineur, A. Azzedine and 5 more. Annals of Oncology, 2008

658 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/595d9d7c9c1dc593a23ebf9d14b7a434fffde116

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Benson
2. M. Suker
3. T. Conroy
4. A. Wang-Gillam
5. R. Ramanathan
6. Berend R. Beumer
7. E. Sadot
8. S. Alberts

Citations in the corpus

• A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer (2016, background): “The aim of this paper was to perform a systematic review and patient-level meta-analysis to evaluate FOLFIRINOX as first-line treatment for patients diagnosed with LAPC.”
• Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. (2011, result): “03).(5) Median OS in the gemcitabine-alone arm (13 months) was unusual for patients with locally advanced disease, as reported in other randomized trials.”